Marinus Pharmaceuticals Presented Data From Phase 3 RAISE At Neurocritical Care Society Annual Meeting; Median Time To SE Cessation Was 4.2 Minutes In Patients Treated With IV Ganaxolone vs 307.2 Minutes For Placebo
Portfolio Pulse from Benzinga Newsdesk
Marinus Pharmaceuticals presented promising Phase 3 RAISE trial data at the Neurocritical Care Society Annual Meeting, showing that their IV Ganaxolone significantly reduced the median time to status epilepticus cessation to 4.2 minutes compared to 307.2 minutes for placebo.
October 17, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marinus Pharmaceuticals' IV Ganaxolone demonstrated a significant reduction in time to status epilepticus cessation in Phase 3 RAISE trial, potentially boosting investor confidence and stock price.
The Phase 3 RAISE trial results are a critical milestone for Marinus Pharmaceuticals, demonstrating the efficacy of IV Ganaxolone in significantly reducing the time to status epilepticus cessation. This positive data is likely to enhance investor confidence and could lead to an increase in the stock price as it suggests a strong potential for the drug's success in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100